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basal ganglia; medium spiny neuron; selective serotonin reuptake inhibitor; 5-HT 1B receptor sensitization; substantia nigra pars reticulata THE SUBSTANTIA NIGRA PARS RETICULATA (SNr) is a critical node in the vast cortico-basal ganglia-thalamo-cortical (CBGTC) loop (Fig. 1A ) (Haber 2003; Hikosaka 2007) that is important to motor control (Friend and Kravitz 2014) and also to cognition (Simpson et al. 2010) , emotion (Marchand et al. 2012; Révy et al. 2014) , and learning and habit formation (Graybiel and Smith 2014; Sesack and Grace 2010) . A main characteristic of the SNr is that its GABA projection neurons fire autonomous high-frequency spikes that are paused by the massive GABA input from the striatonigral projection (Hikosaka et al. 2000 (Hikosaka et al. , 2014 Sano et al. 2013; Schultz 1986; Zhou and Lee 2011) . Another prominent anatomic feature of the SNr is its dense serotonin (5-HT) innervation, originated in the dorsal raphe ( Fig. 1B) (Moukhles et al. 1997; Parent et al. 2011) . 5-HT neurons fire tonic spikes at 1-2 Hz, likely leading to spontaneous tonic 5-HT release and an ambient 5-HT level in the SNr (Jacobs and Azmitia 1992) . Matching the heavy 5-HT innervation, the SNr has an expression of 5-HT type 1B receptors (5-HT 1B Rs) on the striatonigral axon terminals that is the highest in the brain (Fig. 1C) (Boschert et al. 1994; Ding and Zhou 2014; Maroteaux et al. 1992; Riad et al. 2000; Sari, 2004; Voigt et al. 1991) . 5-HT 1B Rs are commonly coupled to the G i/o protein and are inhibitory (Hannon and Hoyer 2008) . Thus there is an anatomic basis for 5-HT to inhibit striatonigral GABA output.
Another key feature of the SNr is the densely expressed 5-HT transporters (SERTs) on the 5-HT axons (Fig. 1B) . SERTs are the target of selective 5-HT reuptake inhibitor (SSRI)-based antidepressant treatment (Wong et al. 2005) . SSRIs block SERT-mediated 5-HT reuptake and increase the extracellular 5-HT level (Wong et al. 2005) . Chronic increase in the extracellular 5-HT level can desensitize the 5-HT 1A and 5-HT 1B autoreceptors in 5-HT neurons and their axon terminals via diminished receptor-G protein coupling (Castro et al. 2003; Cornelisse et al. 2007; Hensler 2002) or receptor internalization (Descarries and Riad 2012) , thus contributing to their antidepressant effect (Blier and El Mansari 2013) , although the precise neuronal mechanisms are not established for either depression or antidepressant treatment.
To our knowledge, although studies have examined the molecular and behavioral aspects of 5-HT 1B Rs in the brain (Zhuang et al. 1999; Woehrle et al. 2013) , neurophysiological studies on chronic SSRI effects on presynaptic 5-HT 1 heteroreceptors on non-5-HT axon terminals are lacking, and currently there are no data on the potential chronic SSRI treatment-induced alteration of the 5-HT 1B Rs on the striatonigral axon terminals. Given the importance of the nigral node in the emotion-regulating cortico-basal ganglia-thalamo-cortical (CBGTC) loop (Marchand et al. 2012) , it is critical to understand how chronic SSRI treatment affects these 5-HT 1B Rs and the functional consequences. Based on the prevailing idea that 5-HT 1 autoreceptors are desensitized following chronic SSRI-type antidepressant (Blier and El Mansari 2013; Descarries and Riad 2012; Newman et al. 2004) , we initially reasoned that chronic SSRI treatment may desensitize 5-HT 1B Rs on the striatonigral axon terminals; our data, however, indicate a substantial sensitization, a novel finding that is the opposite of the changes for 5-HT 1 autoreceptors reported in the literature.
MATERIALS AND METHODS

Electrophysiology
Preparation of brain slices. Wild-type 25-to 35-day-old male and female C57BL mice were used. Equal numbers of male and female mice were used; no difference in 5-HT effects was noticed and data were pooled. Young mice were used because brain slices from young animals survive tissue sectioning better and thus facilitate recording.
We have determined that the baseline 5-HT 1B effect was stable during this period. Additionally, it has been reported that in rodents, the 5-HT system develops rapidly, reaching adult levels at postnatal day 21 (Murrin et al. 2007) , and SSRIs produced antidepressant-like effects in 21-day old juvenile rats (Reed et al. 2008) . Furthermore, depression is a common psychiatric disorder in children and adolescents, and SSRIs are the common pharmacological treatment (Birmaher 2014; Kennard et al. 2014; Kessler et al. 2001; March et al. 2004) . Thus data from juvenile and adolescent animals are important.
All procedures were carried out in accordance with Institutional Animal Care and Use Committee of The University of Tennessee Health Science Center (UTHSC) and followed the guidelines of the National Institutes of Health. The procedure to prepare 15°angular sagittal slices containing the SNr, the external globus pallidus (GPe), and the striatum ( Fig. 2A ) has been described in detail (Connelly et al. 2010; Ding et al. 2013 Ding et al. , 2015 . Briefly, mice were killed by decapitation under deep anesthesia, and brains were quickly dissected out and immediately immersed in an oxygenated ice-cold cutting solution containing (in mM) 220 glycerol, 2.5 KCl, 1.25 NaH 2 PO 4 , 25 NaHCO 3 , 0.5 CaCl 2 , 7 MgCl 2 , and 20 D-glucose. Parasagittal slices 300 m thick were cut on a Leica Zero Z VT1200S vibratome (Leica Microsystems, Wetzlar, Germany) at a 15°angle to the sagittal plane using a precision metal wedge. The brain slices were transferred to a holding chamber filled with a standard artificial cerebrospinal fluid (ACSF; in mM: 125 NaCl, 2.5 KCl, 25 NaHCO 3 , 1.25 NaH 2 PO 4 , 2.5 CaCl 2 , 1.3 MgCl 2 , and 10 D-glucose) that was kept at 34°C and continuously bubbled with 95% O 2 and 5% CO 2 . After an initial 30-min incubation at 34°C, the brain slices were kept at room temperature (25°C). Ascorbic acid (0.4 mM) was added to all brain slice-bathing solutions, including the cutting solution to protect the tissue (Rice 1999).
Fluoxetine treatment. Fluoxetine hydrochloride was dissolved in distilled and autoclaved water and then administered subcutaneously with a daily dose of 20 mg/kg. Briefly, starting on postnatal day 15, male and female C57BL mice received 2 subcutaneous doses of 10 mg/kg fluoxetine at 8:00 AM and 5:00 PM. Injection of 0.9% NaCl saline served as control. Mice were killed at 10:00 AM on the appropriate treatment days. For 1-day treatment to test the acute effect of fluoxetine, mice received the first fluoxetine injection at 5:00 PM the day before and the second fluoxetine injection at 8:00 AM on the day of experiment and were killed 2 h later. To test the effect of chronic fluoxetine treatment, mice received fluoxetine treatment for up to 20 days; the effects during 10 -20 days were similar, and the data from these treatment days were pooled. The daily 20 mg/kg fluoxetine dose was chosen because literature reports indicate that 5-30 mg· kg Ϫ1 ·day Ϫ1 fluoxetine produces antidepressant-like effects (Cryan et al. 2005 ) and also biochemical changes in 5-HT 1A R and 5-HT 1B R signaling pathways (Hensler 2002; Le Poul et al. 2000; Pejchal et al. 2002; Shen et al. 2002) . This dose did not affect the body weight of the mice. A protocol of two subcutaneous injections per day was chosen because the blood half-life of fluoxetine in rodents is only about 6 h, whereas it is 12 h in nonhuman primates and 2 days in humans (Ansorge et al. 2008; Czachura and Rasmussen 2000; Hirano et al. 2005; Sawyer and Howell 2011) .
Whole cell patch-clamp recording. Slices were placed in a recording chamber mounted on the microscope stage and continuously perfused at 2 ml/min with the standard ACSF saturated with 95% O 2 and 5% CO 2 . Recordings were made at 30°C (TC 324B temperature controller; Warner Instruments) under visual guidance of a video Fig. 1 . Serotonin (5-HT) innervation and 5-HT type 1B receptor (5-HT 1B R) expression in the substantia nigra pars reticulata (SNr). A: circuit diagram showing the position of the striatonigral projection in the cortico-basal ganglia-thalamo-cortical (CBGTC) loop. B: strikingly dense 5-HT innervation in the SNr revealed by serotonin transporter (SERT) immunostaining in coronal brain sections. C: relatively dense 5-HT 1B R expression in the SNr revealed by 5-HT 1B R immunostaining in coronal brain sections. As described in MATERIALS AND METHODS, B and C show results obtained with different staining methods in different tissue sections from two 50-day-old male mice. These images illustrate the point that the SNr had an exceptionally dense 5-HT innervation and a relatively heavy expression of 5-HT 1B Rs in our experimental mice. Hippo, hippocampus; SNc, substantia nigra pars compacta; VTA, ventral tegmental area.
microscope (an Olympus BX51WI and a Zeiss Axiocam MRm digital camera) equipped with Nomarski optics and a ϫ60 water-immersion lens (Fig. 2B) . Patch pipettes were pulled from borosilicate glass capillary tubing (KG-33, 1.1-mm inner diameter, 1.65-mm outer diameter; King Precision Glass, Claremont, CA) using a PC-10 puller (Narishige, Tokyo, Japan) and had resistances of 1.5-2.5 M⍀ when filled with one of the following intracellular solutions. A KCl-based intracellular solution (in mM: 135 KCl, 0.5 EGTA, 10 HEPES, 2 Mg-ATP, 0.2 Na-GTP, and 4 Na 2 -phosphocreatine, pH 7.25, 280 -290 mosM) was used to record inhibitory postsynaptic currents (IPSCs) in voltage-clamp recording mode. To record hyperpolarizing inhibitory postsynaptic potentials (IPSPs) in current-clamp mode, we used a KMeSO 4 -based intracellular solution (in mM: 130 KMeSO 4 , 5 KCl, 0.5 EGTA, 10 HEPES, 2 Mg-ATP, 0.2 Na-GTP, and 4 Na 2 -phosphocreatine, pH 7.25, 280 -290 mosM). When evoked IPSCs were recorded, the Na ϩ channel blocker lidocaine N-ethyl bromide (5 mM) was added to the intracellular solution to block Na ϩ spikes. All recordings were made in the presence of 10 M 6,7-dinitroquinoxaline-2,3-dione and 20 M 2-amino-5-phosphonovaleric acid to block ionotropic glutamate receptors.
Electrical stimulation to evoke synaptic responses. To evoke striatonigral IPSCs, a bipolar tungsten electrode (Microprobes, Gaithersburg, Maryland) was placed in the striatum. A paired pulse with an interpulse interval of 50 ms was generated by a Master-8 pulse generator (A.M.P.I., Jerusalem, Israel) and delivered at 0.05 Hz. The stimulation intensity was from 50 to 300 A at a constant duration of 0.2 ms. To evoke pallidonigral IPSCs, a minimal stimulation method was used to minimize the activation of the passing striatonigral axons. Briefly, a theta capillary pipette with a tip diameter of 5 m was placed in the GPe. Paired pulses with an inter pulse interval of 50 ms were delivered at 0.05 Hz. The stimulation intensities ranging from 10 to 50 A were first adjusted to elicit all-or-none IPSCs with 20 -50% failure rate. The stimulation intensities were then increased a few microamperes to decrease the failure rate to Ͻ10%.
Data acquisition and analysis.
A Multiclamp 700B amplifier, pClamp 9.2 software, and Digidata 1322A interface (Molecular Devices, Sunnyvale, CA) were used to acquire data. For voltage-clamp recording, cells were held at Ϫ70 mV, leading to inward IPSCs with our KCl-based intracellular solution. Access resistance was monitored by a 10-mV, 50-ms pulse before every evoked IPSC. Cells in which the access resistance increased by Ͼ15% were discarded. Liquid junction potentials were not corrected because our experimental questions did not have any voltage dependence.
The peak IPSC amplitudes were measured using Clampfit 9.2 software. Averages of 10 consecutive IPSCs before or during drug administration were used to evaluate baseline and drug response, respectively. Paired-pulse ratio (PPR) was calculated by dividing the peak amplitude of the second IPSCs by the peak amplitude of the first IPSCs. To analyze the effect of a train of IPSPs on spontaneous firing of SNr GABA neuron, the spike number during the 300 ms immediately after the first stimulation artifact was measured.
To obtain the IC 50 , we fitted the averaged data points in the doseresponse plot to the Hill equation:
, where A is the maximal inhibition, X is the 5-HT concentration, and K is the IC 50 .
Drugs. All drugs used in electrophysiology experiments were made into stock solutions in ddH 2 O or dimethyl sulfoxide. Stock solutions of drugs were diluted at least 1:1,000 to the desired concentration in ACSF immediately before their application. DL-2-Amino-5-phosphonovalerate, 6-cyano-7-nitroquinoxaline-2,3-dione, lidocaine N-ethyl bromide (QX-314), 5-HT, picrotoxin, CP93129, and NAS-181 were purchased from either Tocris or Sigma-Aldrich. Drugs were bath-applied. Fluoxetine hydrochloride was also obtained from the National Institute of Mental Health Chemical Synthesis and Drug Supply Program.
Immunohistochemistry
Serotonin transporter immunostain. Under overdose urethane anesthesia, 40-to 50-day-old mice (n ϭ 3) were intracardially perfused objective. The SNr, GP, and striatum are clearly identifiable. Other structures such as the thalamus (Thal) and zona incerta (ZI) are also clearly visible, as marked. B: image taken under a ϫ60 objective shows a typical SNr GABA neuron being patchclamped in cell-attached mode. C: typical spontaneous spikes (action potentials, ϳ17 Hz) in a presumed SNr GABA neuron recorded in cell-attached mode. D: independent elicitation of striatonigral IPSCs and pallidonigral IPSCs. D1 and D2: example traces of striatum-evoked typical striatonigral facilitating IPSCs and GP-evoked depressing pallidonigral IPSCs, respectively. Timescale applies to both striatonigral IPSCs and pallidonigral IPSCs. D3: pooled data for paired-pulse ratios (PPR; P1 and P2, pulse 1 and pulse 2) and latencies of the first evoked IPSCs induced by a paired-pulse protocol with an interval of 50 ms for striatonigral IPSCs and pallidonigral IPSCs. For striatonigral IPSC data, n ϭ26 cells from 26 brain slices of 22 mice; for pallidonigral IPSC data, n ϭ 11 cells from 11 brain slices of 11 mice.
with phosphate-buffered saline (PBS) and then with 4% paraformaldehyde dissolved in PBS. The brains were further postfixed in the same 4% paraformaldehyde at 4°C overnight. Coronal brain sections (50 m thick) were cut on a Leica VT1200S vibratome. Free-floating sections were incubated with 2% fat-free milk, 1% bovine serum albumin (BSA), and 0.4% Triton X-100 in PBS for 1 h at room temperature (RT) to block nonspecific binding and permeabilize the cell membrane, respectively. After thorough rinsing, the free-floating sections were incubated for 48 h at 4°C with the primary antibody (see below) and then rinsed in PBS three times for 5 min each, followed by incubation with the secondary antibody (see below) for 3 h at RT in the dark. Both the primary and secondary antigen-antibody reactions occurred in PBS containing 3% normal donkey serum, 1% BSA, and 0.1% Triton X-100. The primary antibody was a polyclonal SERT antibody raised in goat (Santa Cruz Biotechnology; diluted at 1:800). The secondary antibody was a donkey anti-goat IgG antibody conjugated with red Alexa Fluor 568 (diluted at 1:200). At the age of the mice used here, SERT immunostain reliably labels SERT-expressing 5-HT axon terminals (Nielsen et al. 2006) .
5-HT 1B R immunostain.
Under overdose urethane anesthesia, mice were intracardially perfused with PBS. For this particular antigen and antibody pair, we used the following procedure to enhance the detection of 5-HT 1B R protein. The brains were quickly dissected out and immediately frozen and stored at Ϫ80°C. Brains were sectioned on a Leica cryostat at 20-m thickness. The sections were collected onto Superfrost Plus microscope slides (Fisher Scientific) and stored at Ϫ80°C until use. To process the tissue sections for 5-HT 1B R immunostain, the slides were removed from Ϫ80°C, quickly thawed, air-dried, and lightly fixed in 4% paraformaldehyde for 6 min, then in Bouin's solution for 5 min, and finally in 80% ethanol for 5 min. These sections were then incubated in 2% fat-free milk, 1% BSA, and 0.4% Triton X-100 in PBS for 1 h at RT to block nonspecific binding and permeabilize the cell membrane, respectively. After thorough rinsing, the sections were incubated for 48 h at 4°C with the primary antibody (see below) and then rinsed in PBS three times for 5 min each, followed by incubation with the secondary antibody (see below) for 3 h at RT in the dark. Both the primary and secondary antigenantibody reactions occurred in PBS containing 3% normal donkey serum, 1% BSA, and 0.2% Triton X-100. The primary antibody was a polyclonal 5-HT 1B R antibody raised in rabbit (Santa Cruz Biotechnology; diluted at 1:1,000). The secondary antibody was donkey anti-rabbit IgG antibody conjugated with green Alexa Fluor 488 (Invitrogen; diluted at 1:200).
Fluorescence images were acquired on a Zeiss 710 laser scanning confocal microscope at the UTHSC Neuroscience Imaging Center (Memphis, TN).
Statistics
Data are means Ϯ SE. The paired t-test was used to make comparisons of evoked events before and during drug administration. Unpaired t-test, one-way ANOVA, and two-way ANOVA were also used when appropriate. When two-way ANOVA was used, drug treatment and dose of 5-HT were the independent variables. A P value Ͻ0.05 was considered statistically significant.
RESULTS
Independent Elicitation of Striatonigral and Pallidonigral IPSCs
The main neuron type in the SNr is the GABA projection neurons that fire spontaneously around 10 Hz under in vitro conditions (Atherton and Bevan 2005; Ding et al. 2011a Ding et al. , 2011b ; Zhou and Lee 2011). The SNr also contains sparse dopamine neurons that fire spontaneously around 1.5 Hz under similar in vitro conditions (Connelly et al. 2010; Ding et al. 2011a Ding et al. , 2011b Zhou et al. 2006) . Therefore, we first briefly recorded action potentials of neurons in SNr in a cell-attached mode in our angular sagittal brain slices (Fig. 2, A-C) . Neurons in the SNr with a spontaneous firing rate Ն5 Hz were presumed to be GABA neurons (Connelly et al. 2010; Ding et al. 2011a Ding et al. , 2011b Zhou et al. 2006) . After cell identification, we proceeded to whole cell recording mode and started striatal or GPe stimulation to activate striatonigral or pallidonigral GABAergic transmission, respectively. As shown in Fig. 2D , focal stimulation in the striatum consistently evoked IPSCs in SNr GABA neurons. These evoked IPSCs and also the spontaneous IPSCs were blocked by bath-applied picrotoxin (100 M), indicating that these IPSCs were mediated by GABA A receptors, as expected. Focal GPe minimal stimulation also consistently evoked IPSCs in SNr GABA neurons that were blocked by bath-applied 100 M picrotoxin, too.
We also used low-intensity stimuli and a paired-pulse protocol to ensure that our focal stimulation in the dorsal striatum and in the GPe evoked isolated striatonigral IPSCs and pallidonigral IPSCs, respectively. We found that in our sampled cells, as shown in Fig. 2D , the latency was 7.8 Ϯ 0.2 ms (n ϭ 23 cells) for the striatum-evoked IPSCs and 2.5 Ϯ 0.2 ms (n ϭ 11) for GPe-evoked IPSCs (unpaired t-test, P Ͻ 0.000 for the 2 latency values). The PPR was 1.6 Ϯ 0.1 (n ϭ 23 cells) for the striatum-evoked IPSCs and 0.7 Ϯ 0.1 (n ϭ 11 cells) for GPe-evoked IPSCs (unpaired t-test, P Ͻ 0.000 for the 2 PPR values). These are consistent with data showing that the striatonigral IPSC has a long latency (ϳ7 ms, due to the longdistance pathway) and a facilitating PPR (ϳ2), whereas pallidonigral IPSC had a short latency (ϳ2 ms) and a depressing PPR (ϳ0.7) (Connelly et al. 2010; Ding et al. 2015) . Thus, under our experimental conditions, the striatum-evoked IPSCs in SNr GABA neurons were predominantly striatonigral IPSCs, whereas the GPe-evoked IPSCs in SNr GABA neurons were predominantly pallidonigral IPSCs. This allowed us to study 5-HT effects on these relatively pure striatonigral IPSCs and pallidonigral IPSCs.
5-HT Inhibits Striatonigral IPSCs via a Presynaptic Mechanism
After obtaining a stable baseline recording of striatonigral IPSCs, we started bath application of 5-HT. We initially used 10 M 5-HT and found that it reduced the striatonigral IPSC amplitude by a profound 94% on the average (Fig. 3A) . By using 5-HT concentrations ranging 0.5 to 20 M, we determined that 5-HT inhibited striatonigral IPSCs in a doseresponse manner with an IC 50 of 1.2 M and a Hill coefficient of 1.3, based on fitting the data points to the Hill equation (Fig.  3, A and C) . In contrast, bath application of 0.5 to 20 M 5-HT did not significantly affect pallidonigral IPSCs (Fig. 3, B and C). These results indicate that 5-HT can potently inhibit the striatonigral GABAergic transmissions while having no effect on the pallidonigral GABAergic transmissions.
Next, we determined if 5-HT was reducing the striatonigral IPSC amplitude by a presynaptic mechanism. To answer this question, we used a paired-pulse protocol with a pair of stimulating pulses separated by 50 ms (20 Hz). This frequency was chosen because 20 Hz is a common firing frequency when the striatonigral neurons are phasically active in freely moving mice (Miller et al. 2008; unpublished data, Sagot B and Zhou F.-M.) . Using this paired-pulse protocol, we found that under control conditions, striatonigral IPSCs exhibited a paired-pulse facilitation with a PPR value of 1.66 Ϯ 0.22 (Fig. 3, D1 and D4). During bath application of 5 M 5-HT, the peak amplitude of the first of the paired striatonigral IPSCs was reduced to a larger extent than that of the second IPSC, thus increasing the PPR from 1.66 Ϯ 0.22 under control conditions to 4.10 Ϯ 0.67 during 5-HT application (P Ͻ 0.05, paired t-test, n ϭ 6; Fig. 3, D2-D4 ). Because an increased PPR is an indication of inhibition of presynaptic vesicular release (Fioravante and Regehr 2011) , these results suggest that 5-HT inhibits striatonigral IPSCs by acting presynaptically to inhibit transmitter release. To further support our conclusion of presynaptic 5-HT inhibition of GABA release of the striatonigral axon terminals, we calculated the coefficient of variation (CV) of the striatonigral IPSCs by dividing the standard deviation by the mean of the 10 or more individual IPSCs, as described in Michaeli and Yaka (2010) . Under control conditions, the baseline CV was 0.43 Ϯ 0.08 (n ϭ 6 cells); during 5 M 5-HT application, the CV was increased to 0.78 Ϯ 0.05. The increase in CV was significant with P Ͻ 0.05 (paired t-test), indicating a decreased vesicular release probability during application of 5 M 5-HT application.
5-HT 1B Agonism Mimics and 5-HT 1B Antagonism Blocks 5-HT Effects on Striatonigral IPSCs
Next, we asked this question: Are presynaptic 5-HT 1B Rs mediating the inhibitory effect of 5-HT on striatonigral IPSCs? To answer this question, we evoked striatonigral IPSCs with the same paired-pulse protocol described above and bathapplied 1 M CP93129, a 5-HT 1B R agonist. As shown in Fig.  4A , after bath application of 1 M CP93129, the peak amplitude of the first of the paired striatonigral IPSCs was reduced to 11.0 Ϯ 3.0% of control, a 89% reduction (P Ͻ 0.000, paired t-test, n ϭ 6). Similar to the effect of 5-HT, 1 M CP93129 significantly increased the PPR from 1.67 Ϯ 0.21 to 4.08 Ϯ 0.72 (P Ͻ 0.05, paired t-test, n ϭ 6), indicating a presynaptic 5-HT 1B R-mediated inhibition of vesicular GABA release. This is consistent with the literature reporting that 5-HT 1B R activation decreases vesicular transmitter release (Mizutani et al. 2006 ).
Furthermore, we tested if NAS-181, a 5-HT 1B R antagonist, can block the effect of 5-HT on striatonigral IPSCs. As shown in Fig. 4 , E and F, bath application of 5 M 5-HT reduced the striatonigral IPSCs to 18.0 Ϯ 3.0% of control, a 82% reduction (P Ͻ 0.0001, paired t-test, n ϭ 6). Bath application of 10 M NAS-181 almost completely blocked the inhibitory effect of 5 M 5-HT, restoring the striatonigral IPSC amplitude to 87.5 Ϯ 10.1% of control (P Ͻ 0.005, paired t-test, n ϭ 6; Fig. 4, E and  F) . Taken together, these results indicate that 5-HT potently inhibits the striatonigral IPSCs through the presynaptic 5-HT 1B Rs on striatonigral axon terminals.
5-HT and 5-HT 1B Receptor Agonist CP93129 Reduces the Striatonigral Inhibition of SNr GABA Neuron Firing
Next, we examined the functional consequences of the robust presynaptic 5-HT 1B R inhibition of the GABA release from striatonigral axon terminals, a critical issue that had never been studied. We predicted that 5-HT may reduce the inhibitory effect of striatonigral IPSPs on the spontaneous firing of SNr GABA neurons. To test this idea, we evoked a train of 5 striatonigral IPSPs by a train of 5 stimuli at 20 Hz, mimicking a common firing pattern of the striatonigral neurons in freely moving mice (Miller et al. 2008 ; unpublished data, Sagot B and Zhou F.-M.). As shown in Fig. 5, A and B, under the control conditions, the striatonigral IPSP train strongly inhibited or paused the spontaneous firing of SNr GABA neurons. After bath application of 5 M 5-HT, the amplitude of the striatonigral IPSPs, and hence the effect of the striatonigral IPSPs on the spontaneous firing of SNr GABA neurons, was reduced substantially. To quantify the effect of 5-HT on the striatonigral IPSP-induced pause in SNr GABA neurons, we calculated the spike number in the 300-ms window that starts at the first stimulus, as illustrated in Fig. 5 . The spike number in the 300-ms window was only 0.23 Ϯ 0.14 (spike firing was almost completely inhibited or paused) under control conditions, but it was increased to 2.20 Ϯ 0.43 under 5 M 5-HT (the pause was substantially reduced) (P Ͻ 0.005, paired t-test, n ϭ 6). This effect is likely mediated by presynaptic 5-HT 1B Rs that inhibit the striatonigral IPSPs. At the same time, bath application of 5 M 5-HT significantly increased the baseline spontaneous firing of SNr GABA neurons from 8.4 Ϯ 1.7 to 16.7 Ϯ 1.8 Hz (P Ͻ 0.001, paired t-test, n ϭ 6), probably through activation of postsynaptic 5-HT 2C receptors known to express in SNr GABA neurons (Clemett et al. 2000) .
To further test our idea, we studied the effect of the 5-HT 1B agonist CP93129 on striatonigral IPSP-induced pause in the spontaneous firing of SNr GABA neurons with the same stimulation protocol. As shown in Fig. 5, A4 , A5, B4, and B5, the spike number in the 300-ms window was 0.23 Ϯ 0.13 under control conditions and increased to 2.58 Ϯ 0.38 during bath application of 5 M CP93129 (P Ͻ 0.001, paired t-test, n ϭ 8). The effect was recovered upon washing out 5 M CP93129. Unlike 5-HT, 5 M CP93129 had no significant effect on the baseline spontaneous firing of SNr GABA neurons (10.4 Ϯ 1.4 Hz under control vs. 11.2 Ϯ 1.6 Hz under CP93129, P Ͼ 0.05, paired t-test, n ϭ 8), because SNr GABA neurons are not known to express postsynaptic 5-HT 1B Rs (Sari 2004 ). Together, these results suggest that 5-HT can reduce striatonigral IPSPs by activating the presynaptic 5-HT 1B Rs and soften the pausing effect of the striatonigral output on the spontaneous high-frequency firing in SNr GABA neurons.
Chronic Fluoxetine Treatment Sensitizes 5-HT 1B Rs on Striatonigral Axon Terminals
To determine the potential effects of chronic SSRI treatment on the functional status of the 5-HT 1B Rs on striatonigral axon terminals, we injected mice with either saline or fluoxetine Fig. 4 . 5-HT 1B R agonist CP93129 mimics and 5-HT 1B R antagonist NAS-181 inhibits the 5-HT effects on striatonigral IPSCs. A1: superimposed averaged striatonigral IPSCs evoked by the paired-pulse protocol before (control), during (CP93129), and after (wash) 1 M CP93129 application. A2: current traces in A1 normalized to the peak of the 1st IPSC in each pair to show clearly that the 2nd IPSC is increased during 1 M CP93129 application, leading to increased PPR. A3: pooled data showing the inhibitory effect of 1 M CP93129 on the peak amplitude of the 1st of the paired IPSCs in 6 SNr GABA neurons. A4: pooled data showing the increased PPR during 1 M CP93129 in the 6 SNr GABA neurons. B: 5-HT 1B R antagonist NAS-181 blocked the effect of 5-HT on striatonigral IPSCs. B1: superimposed averaged IPSCs evoked by striatum stimulation before (control) and during application of 5 M 5-HT or 10 M NAS-181 ϩ 5 M 5-HT (NAS181ϩ5-HT). B2: pooled data showing the blockade effect of NAS-181 on the effect of 5-HT on striatonigral IPSCs (n ϭ 6 neurons from 6 brain slices of 5 mice). using the protocol described in MATERIALS AND METHODS. The effects during 10 -20 days were similar, and thus data from these treatment days were pooled. As shown in Fig. 6 , A-C, 5-HT inhibited the striatonigral IPSCs in a dose-dependent manner in both chronically fluoxetine-treated and salinetreated mice [2-way ANOVA, F (7) ϭ 38.826, P ϭ 0.000]. However, at 0.5 M, 5-HT reduced the striatonigral IPSC by 79.3 Ϯ 5.2% (n ϭ 6) in chronically fluoxetine-treated mice and by only 16.1 Ϯ 9.9% (n ϭ 6) in saline-treated mice [2-way ANOVA, F (1,71) ϭ 66.56, P ϭ 0.000]. Similarly, at 1 M, 5-HT inhibited the striatonigral IPSC to a larger extent in chronically fluoxetine-treated mice than in saline-treated mice [85.4 Ϯ 5.3% for fluoxetine-treated mice (n ϭ 6) and 40.9 Ϯ 4.7% for saline-treated mice (n ϭ 7); 2-way ANOVA, F (1,71) ϭ 35.65, P ϭ 0.000]. At 3 M, 5-HT also had larger inhibitory effects on the striatonigral IPSCs in chronically fluoxetinetreated mice than in age-matched saline-treated mice [89.8 Ϯ 3.9 and 66.3 Ϯ 7.3% for fluoxetine-treated mice and salinetreated mice, respectively (n ϭ 6 in each group); 2-way ANOVA, F (1,71) ϭ 9.21, P ϭ 0.0034]. However, at 5, 10, and 20 M, the 5-HT inhibition of the striatonigral IPSCs was a similarly total or near total in both chronically fluoxetinetreated and saline-treated mice [2-way ANOVA, F (1,71) ϭ 2.01, 0.07, and 0.11, P ϭ 0.16, 0.80, and 0.74 for 5, 10, and 20 M 5-HT, respectively]. When we fitted these data points to the Hill equation, we found that the IC 50 was 0.24 Ϯ 0.01 and 1.4 Ϯ 0.2 M for fluoxetine-treated mice and saline-treated mice, respectively (Fig. 6C ). There was a clear leftward shift in the dose-response curve of 5-HT inhibition of the striatonigral IPSCs in chronic fluoxetine-treated mice compared with that of the age-matched saline-treated mice, indicating that 5-HT 1B Rs on the striatonigral axon terminals became more sensitive to 5-HT after chronic fluoxetine treatment.
We have also tested the potential effects of 1-day and 7-day fluoxetine treatment (see MATERIALS AND METHODS for dosing details). As shown in Fig. 7 , after 1-day treatment with fluoxetine, 1 M 5-HT inhibited striatonigral IPSC by 44.4 Ϯ 4.5% (n ϭ 6 cells) in mice and by 40.9 Ϯ 4.7% (n ϭ 7 cells) in saline-treated control mice (1-way ANOVA, P Ͼ 0.05). In mice treated with fluoxetine for 7 days, 1 M 5-HT inhibited striatonigral IPSC by 68 Ϯ 4.1% (n ϭ 7), significantly more than in saline-treated control mice and also 1-day fluoxetine treatment mice ( Fig. 7B ; 1-way ANOVA, P Ͻ 0.05). However, compared with that in mice treated with fluoxetine for 10 -20 days (chronic fluoxetine treatment), the inhibitory effect of 1 M 5-HT on striatonigral IPSCs in the 7-day fluoxetine treatment group was significantly smaller (1-way ANOVA, P Ͻ 0.05). Starting on fluoxetine treatment day 10, the 1 M 5-HT-induced inhibition of the striatonigral IPSCs was at 85%, near the maximal 94% inhibition induced by 10 M 5-HT. Thus 10-day fluoxetine treatment-induced sensitization was near the saturating level, and pooling of data from 10 -20 days of treatment was justified. These results indicated that fluoxetine treatment-induced sensitization of 5-HT 1B Rs on the striatonigral axon terminals is a gradual process and that the timeline is similar to that of 5-HT 1A autoreceptor desensitization in 5-HT neurons in intact animals (Blier and De Montigny 1983) .
Chronic Fluoxetine Treatment Upregulates Presynaptic 5-HT 1B R-Mediated Reduction of the Pause in SNr GABA Neuron Firing
Because our data showed that chronic fluoxetine treatment sensitizes 5-HT 1B Rs on the striatonigral axon terminals (Fig.  6) , we reasoned that the same treatment might upregulate 5-HT 1B R-mediated reduction in the striatonigral IPSP-induced pause of SNr GABA neuron firing. To test our hypothesis, we treated mice with saline or fluoxetine using the same protocol described above. In brain slices from these treated mice, we tested the effects of the 5-HT 1B R agonist CP93129 at a low concentration of 0.1 M on the striatonigral IPSP-induced pause in SNr GABA neuron firing; 5-HT was not used in order to avoid 5-HT activation of somatic 5-HT 2C receptors that would increase SNr GABA neuron firing and complicate data interpretation. To quantify the effect of CP93129 on the pause, we measured the pause duration induced by single striatonigral IPSPs. This pause duration was defined as the time window between the artifact of the stimulus that evoked the striatonigral IPSP and the first spike after the stimulus artifact (Fig. 8,  A1 and B1) . Because the pausing effect of the striatonigral IPSP on SNr GABA neuron firing was also dependent on where the IPSP was located on the membrane potential trajectory, in addition to its amplitude, we selected sweeps in which the IPSPs were evoked at the same position on the rising part B: pooled data showing that the inhibitory effect of 1 M 5-HT on striatonigral IPSCs in untreated mice, saline-treated control mice, and mice treated with fluoxetine for 1 day (n ϭ 7 neurons from 7 brain slices of 6 acute fluoxetinetreated mice), 7 days (n ϭ 7 neurons from 7 brain slices of 6 fluoxetine-treated mice for 1 wk), and 10 -20 days. Arrow indicates treatment day 1. FLUOXETINE SENSITIZES 5-HT 1B RECEPTORS of interspike membrane potential trajectory before, during, and after drug application; in these sweeps, we examined how the drug-induced changes in IPSP amplitudes affected the pausing of SNr GABA neuron firing.
We found that bath application of 0.1 M CP93129 reduced the pause duration to 79.6 Ϯ 6.1% of control condition in saline-treated mice [from control pause duration of 79.3 Ϯ 13.7 ms; F (1,5) ϭ 43.678, P Ͻ 0.001, 1-way repeated-measures ANOVA; Fig. 8, A and C] . In chronic fluoxetine-treated mice, 0.1 M CP93129 reduced the pause duration to 57.6 Ϯ 4.6% of control condition [from control pause duration of 93.6 Ϯ 13.7 ms; F (1,5) ϭ 52.281, P Ͻ 0.001, 1-way repeated-measures ANOVA; Fig. 8, B and C] . The effect of 0.1 M CP93129 on the pause was larger in chronic fluoxetine-treated mice than in saline-treated mice (n ϭ 6 for each group, P Ͻ 0.05, unpaired t-test; Fig. 8C ). Also, as expected, bath application of 0.1 M CP93129 reduced the peak amplitude of striatonigral IPSPs to 67.5 Ϯ 10.3% of control in saline-treated mice [from control IPSP amplitude of 8.8 Ϯ 1.4 mV; F (1,5) ϭ32.497, P Ͻ 0.001, 1-way repeated-measures ANOVA] and to 27.7 Ϯ 10.3% of control in chronic fluoxetine-treated mice [from control IPSP amplitude of 9.7 Ϯ 2.4 mV; F (1,5) ϭ 5.83, P Ͻ 0.05, 1-way repeated-measures ANOVA; Fig. 8D ], and this effect was also larger in chronic fluoxetine-treated mice than in saline-treated mice (n ϭ 6 for each group, P Ͻ 0.05, unpaired t-test). Additionally, saline or fluoxetine treatment did not alter the basal firing frequency of SNr GABA neurons recorded in our brain slices; CP93129 also did not affect the spontaneous firing in these neurons: in saline-treated mice, the spontaneous firing rate was 9.95 Ϯ 1.1 Hz under control, 10.9 Ϯ 1.6 Hz under 0.1 M CP93129, and 10.5 Ϯ 1.4 Hz after washout; in fluoxetinetreated mice, the spontaneous firing rate was 11.1 Ϯ 1.5 Hz under control, 12.1 Ϯ 2.0 Hz under 0.1 M CP93129, and 12.1 Ϯ 2.2 Hz after washout. Together, these data clearly indicate that 5-HT 1B R-mediated reduction of SNr GABA neuron firing pause was enhanced after chronic fluoxetine treatment.
DISCUSSION
The main finding of this study is that 5-HT potently inhibits the striatonigral GABA output via the 5-HT 1B Rs on the striatonigral axon terminals. Consequently, 5-HT reduces the striatonigral IPSP-induced pause of the high-frequency spontaneous firing in SNr GABA neurons. Moreover, after chronic fluoxetine treatment, these 5-HT 1B Rs became more sensitive to pooled data showing that 0.1 M CP93129 reduced the peak amplitude of the striatonigral IPSPs more strongly in chronic fluoxetine-treated mice than in saline-treated mice (n ϭ 6 neurons from 6 slices of 5 fluoxetinetreated mice; n ϭ 7 neurons from 7 slices of 6 saline-treated mice).
5-HT, in contrast to the common, chronic SSRI-induced desensitization of 5-HT 1 autoreceptors. Thus our present study has revealed a novel aspect of chronic SSRI-based antidepressant treatment.
Presynaptic 5-HT 1B Heteroreceptors Potently Reduce Striatonigral GABA Output
We found that 5-HT can completely inhibit the striatonigral IPSCs while not affecting the GPe-evoked pallidonigral IPSCs; 5-HT also increased the PPR. Additionally, the 5-HT effects were mimicked by the 5-HT 1B R agonist CP93129 and blocked by the 5-HT 1B R antagonist NAS-181, clearly indicating that presynaptic 5-HT 1B Rs on striatonigral axon terminals were mediating these effects. Our data are consistent with the anatomic fact that 5-HT 1B Rs are expressed at a high level on the striatonigral axon terminals, whereas 5-HT 1B R gene expression is absent or very low in pallidal neurons (Boschert et al. 1994; Maroteaux et al. 1992; Riad et al. 2000; Sari 2004; Sari et al. 1999; Voigt et al. 1991) . Our results also substantially expand the study of Stanford and Lacey (1996) , who reported that 10 M 5-HT induced a 60% inhibition of locally evoked IPSCs of unknown origin. In our present study, 10 M 5-HT induced a virtually complete (94%) inhibition of the striatum-evoked, relatively pure striatonigral IPSCs while having no effect on the pallidonigral IPSCs. The smaller 5-HT effect of Stanford and Lacey (1996) (60% vs. our 94% inhibition with 10 M 5-HT) is probably due to their activation of mixed striatonigral and pallidonigral IPSCs, because pallidonigral IPSCs are insensitive to the presynaptic 5-HT inhibition. We also provided more compelling pharmacological evidence for the mediation of 5-HT 1B Rs by using the specific 5-HT 1B R agonist CP93129 and antagonist NAS-181.
Presynaptic 5-HT 1B Heteroreceptors Reduce the Pause in High-Frequency Firing in Nigral GABA Neurons
Our present study explored the functional importance of the potent presynaptic 5-HT 1B R inhibition of the GABA release from striatonigral axon terminals, a critical issue that had never been studied until now. We found that striatonigral IPSPs can inhibit or pause the endogenously generated high-frequency firing in SNr GABA neurons, consistent with previous studies (Connelly et al. 2010; Hikosaka et al. 2000 Hikosaka et al. , 2014 Kravitz at al. 2010) . We further demonstrated that 5-HT and the 5-HT 1B R agonist CP93129 reduced striatonigral IPSP-induced pause of the spontaneous high-frequency firing of SNr GABA neurons. This is important because the pause in the high-frequency firing of SNr GABA neurons releases the downstream targets such as the thalamus and brainstem motor nuclei (Basso and Sommer 2011; Hikosaka et al. 2000 Hikosaka et al. , 2014 Kaneda et al. 2008; Kravitz at al. 2010; Sano et al. 2013) , and consequently, a reduction in the pause is likely to affect the activity of these downstream nuclei.
We need to note here that 5-HT has other effects on the SNr. For example, 5-HT increases the basal spontaneous firing in SNr GABA neurons by activating 5-HT 2C receptors in these neurons (Stanford and Lacey 1996; Zhou and Lee 2011) . Additionally, presynaptic 5-HT 1B Rs reduce subthalamic glutamatergic input-induced burst firing in SNr GABA neurons (Ding et al. 2013 ). Clearly, 5-HT exerts different effects on different targets in the SNr but with an apparently common goal: to keep SNr GABA neurons in their default autonomous high-frequency firing state. In other words, 5-HT exerts a homeostatic effect: the 5-HT 2C Rs help SNr GABA neurons maintain their basal high-frequency firing and prevent them from firing too slowly; the 5-HT 1B Rs on the subthalamonigral axon terminals prevent the glutamatergic input from triggering too much firing in SNr GABA neurons; and finally, the 5-HT 1B Rs on the striatonigral axon terminals prevent the striatal GABA input from inhibiting SNr GABA neuron firing too strongly.
Chronic Fluoxetine Treatment Sensitizes 5-HT 1B Rs on Striatonigral Axon Terminals
Our results showed that following chronic fluoxetine treatment, the sensitivity of the presynaptic 5-HT 1B Rs to 5-HT increased substantially, enabling a low dose of 5-HT to more strongly reduce the GABA release from the striatonigral axon terminals. This is a novel cellular mechanism for chronic SSRI treatment that has never been reported before, to our knowledge. The prevailing idea is that SSRIs block SERT-mediated 5-HT reuptake and increase the extracellular 5-HT level that desensitizes the 5-HT 1A and 5-HT 1B inhibitory autoreceptors in 5-HT neurons and their axon terminals via diminished receptor-G protein coupling (Castro et al. 2003; Cornelisse et al. 2007; Hensler 2002) or receptor internalization (Descarries and Riad 2012 ); this in turn leads to sustained increase in extracellular 5-HT and thus contributes to the antidepressant effect of SSRI treatment (Blier and El Mansari 2013; Wong et al. 2005) . Reports indicate that postsynaptic 5-HT 1A Rs may also be desensitized via similar mechanisms (Hensler 2002; Li et al. 1997 ).
Thus we were initially surprised by our results indicating that chronic fluoxetine treatment sensitized the 5-HT 1B Rs on the striatonigral axon terminals. However, we quickly realized that although there is no published study on the potential effects of chronic SSRI treatment on presynaptic 5-HT1 heteroreceptors (presynaptic 5-HT1 receptors on non-5-HT axons), there are reports on the potential effects of chronic SSRI treatment on postsynaptic 5-HT 1 heteroreceptors (5-HT 1 receptors on the somata and dendrites of non-5-HT neurons). In particular, an electrophysiological study indicated that postsynaptic 5-HT 1A receptors in the hippocampal neurons in rats were sensitized by chronic fluoxetine treatment (Beck et al. 1997) . Biochemical studies indicate that chronic SSRI treatment may sensitize postsynaptic 5-HT 1A receptors by increasing the receptor-G protein coupling (Castro et al. 2003; Shen et al. 2002; Zanoveli et al. 2007) , providing a possible molecular basis for our unexpected observation.
Although the mechanisms underlying the sensitization of the presynaptic 5-HT 1B Rs on the striatonigral axon terminals was beyond the scope of our current study, the substantial leftward shift in the dose-response curve (IC 50 changed from 1.4 to 0.2 M; Fig. 6C ) indicates an increased receptor binding affinity or more efficient downstream signaling mechanisms. Because the maximal effect was a total inhibition under both conditions, this parameter is less informative. An alternative and nonexclusive possibility is that the 5-HT 1B R expression at the striatonigral axon terminals is upregulated, also leading to a leftward shift in the dose-response curve. This possibility is consistent with a previous study reporting a 127% increase over the baseline in the 5-HT 1B mRNA level following chronic fluoxetine-treated in rats, although the host cell was not identified (Le Poul et al. 2000) . Thus de novo increase in receptor expression may be another factor that allows lower concentrations of 5-HT to achieve the maximal and total inhibition of the striatonigral IPSC. A third possible mechanism for the increased 5-HT sensitivity or the leftward shift of the 5-HT dose-response curve (Fig. 6C) is an increased plasma membrane insertion on the striatonigral axon terminals after chronic fluoxetine treatment, a process that is opposite to the 5-HT 1A R internalization underlying 5-HT 1A R desensitization (Descarries and Riad 2012).
Functional Implications
We found that 5-HT can almost completely inhibit the GABA release from the striatonigral axon terminal with an IC 50 at 1 M. Although the endogenous 5-HT is unlikely to fully activate these 5-HT 1B Rs, this remarkable capacity, coupled with the intense 5-HT innervation in the SNr, still gives these receptors the power to regulate the striatonigral GABA output both in the normal brain and under pathological conditions and thus has important implications.
An obvious implication is in motor control. It is now established that striatonigral GABA output promotes motor activity by inhibiting the SNr GABA neurons (Friend and Kravtiz 2014; Hikosaka et al. 2000 Hikosaka et al. , 2014 Kravitz et al. 2010) . Our data show that the presynaptic 5-HT 1B Rs serve to reduce this motor-promoting striatonigral GABA output. We speculate that because too much motor activity can be harmful to the animal, these presynaptic 5-HT 1B Rs are expressed there as a safety device to limit the striatonigral output. This may also be an evolutionary purpose for the exceptionally dense 5-HT innervation in the SNr. It will be interesting to determine the functional status of these presynaptic 5-HT 1 Rs in Parkinson's disease when there is a deficient or abnormal striatonigral output and in dyskinetic disorders when there is too much motor activity.
Another implication is in the regulation of emotion and antidepressant treatment. The precise anatomic location of emotional regulation is not known, but a proper function of the CBGTC loop is essential to emotional well-being, and dysfunction of the CBGTC loop is involved in depression pathogenesis (Hamilton et al. 2012; Hamon and Blier 2013; Marchand and Yurgelun-Todd 2010; Price and Drevets 2012) . Aberrant functional connectivity in this loop has been indicated to be a primary pathology in depression (Marchand et al. 2012) . Because the SNr is a narrow gate in the CBGTC loop, the information transfer in the SNr may critically affect the emotional regulation aspect of the loop. When the 5-HT 1B Rs on striatonigral axon terminals are sensitized during chronic SSRI treatment, these 5-HT 1B Rs can reduce GABA release and the striatonigral information transfer in a heightened manner, altering the information processing in the CBGTC loop and potentially contributing to the antidepressant effect of chronic fluoxetine treatment.
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